Noncirrhotic portal hypertension in HIV-infected patients: Unique clinical and pathological findings

AIDS

Volumn 24, Issue 8, 2010, Pages 1171-1176

  Vispo, Eugenia ^a   Moreno, Alberto ^b   Maida, Ivana ^a,c   Barreiro, Pablo ^a   Cuevas, Adrián ^b   Albertos, Sonia ^d   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c UNIVERSITY HOSPITAL OF SASSARI   (Italy)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR PLUS TIPRANAVIR; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER HYPERPLASIA; MALE; PORTAL HYPERTENSION; PORTAL VEIN; PORTAL VEIN OBSTRUCTION; PRIORITY JOURNAL;

ADULT; ANTI-RETROVIRAL AGENTS; DIDANOSINE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIV INFECTIONS; HUMANS; HYPERTENSION, PORTAL; LIVER DISEASES; MALE; MIDDLE AGED;

EID: 77951880387     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283389e26     Document Type: Article

References (31)

1. Weber R, Sabin C, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
2. Thio C, Seaberg E, Skolasky R, Phair J, Visscher B, Muñoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort study (MACS). Lancet 2002; 360:1921-1926. (Pubitemid 35472132)
3. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. Hepatology 1999; 30:1054-1058. (Pubitemid 29342467)
4. Soriano V, Puoti M, Garcia-Gasco P, Rockstroh JK, Benhamou Y, Barreiro P, McGovern B. Antiretroviral drugs and liver injury. AIDS 2008; 22:1-13. (Pubitemid 350301936)
5. Sulkowski M, Mehta S, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19:585-592. (Pubitemid 40543981)
6. Blackard J, Sherman K. HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver?J Viral Hepat 2008; 15:323-330. (Pubitemid 351473633)
7. Brenchley J, Price D, Schacker T, Asher TE, Silvestri G, Rao S, et al. Microbial translocationisa causeofsystemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371. (Pubitemid 44924494)
8. Balagopal A, Philp F, Astemborski J, Block TM, Mehta A, Long R, et al. HIV-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135:226-233.
9. Ingiliz P, Valantin M, Duvivier C, Medja F, Dominguez S, Charlotte F, et al. Liver damage underlying unexplained trans-aminase elevation in HIV-1 monoinfected patients on antire-troviral therapy. Hepatology 2009; 49:436-442.
10. Maida I, Nuñez M, Rios MJ, Mart́?n-Carbonero L, Sotgiu G, Toro C, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006; 42:177-182. (Pubitemid 43884712)
11. Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H, Lascoux-Combe C, Pol S. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007; 21:187-192. (Pubitemid 46036926)
12. Schiano T, Kotler D, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102:2536-2540. (Pubitemid 47631766)
13. Maida I, Garć?a-Gascó P, Sotgiu G, Rios MJ, Vispo ME, Martin-Carbonero L, et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13:103-107. (Pubitemid 351541679)
14. Saifee S, Joelson D, Braude J, Shrestha R, Johnson M, Sellers M, et al. Noncirrhotic portal hypertension in patients with HIV infection. Clin Gastroenterol Hepatol 2008; 6:1167-1169.
15. Kovari H, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P, et al. Association of noncirrhotic portal hypertension in HIV-in-fected persons and antiretroviral therapy with didansoine: a nested case-control study. Clin Infect Dis 2009; 49:626-635.
16. Shastri S, Dubinsky M, Poordad F, Vasiliauskas EA, Geller SA. Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy. Arch Pathol Lab Med 2004; 128:49-53. (Pubitemid 38049566)
17. Seiderer J, Zech C, Diebold J, Schoenberg SO, Brand S, Tillack C, et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol He-patol 2006; 18:553-555. (Pubitemid 43832759)
18. Gisbert J, González-Lama Y, Maté J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007; 102:1518-1527. (Pubitemid 46976279)
19. de Boer N, van Bodergraven A, Jharap B, de Graaf P, Mulder C. Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol 2007; 4:686-694. (Pubitemid 350199222)
20. Nakanuma Y, Hoso M, Sasaki M, Terada T, Katayanagi K, Nonomura A, et al. Histopathology of the liver in noncirrhotic portal hypertension of unknown aetiology. Histopathology 1996; 28:195-204. (Pubitemid 26091910)
21. Hillaire S, Bonte E, Denninger M, Casadevall N, Cadranel JF, Lebrec D, et al. Idiopathic noncirrhotic intrahepatic portal hypertension in the west: a re-evaluation in 28 patients. Gut 2002; 51:275-280. (Pubitemid 34791461)
22. Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007; 56:1404-1409. (Pubitemid 47517834)
23. D.A.D. Study Group, Sabin CA, Worm SW, WeberR,ReissP,El-Sadr W, Dabis F, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multicohort collaboration. Lancet 2008; 371:1417-1426.
24. Kuller L, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
25. SMART/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008 22 F17-F24.
26. Goicoechea M, McCutchan A. Abacavir and increased risk of myocardial infarction. Lancet 2008; 372:803-804.
27. Mallet V, Varthaman A, Lasne D, Viard JP, Gouya H, Borgel D, et al. HIV-associated nodular regenerative hyperplasia is linked to portal obstructive venopathy and autoimmune protein S deficiency. Hepatology 2007; 46 (Suppl):576A.
28. Jiang W, Lederman M, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 2009; 199:1177-1185.
29. Koziel M, Peters M. Viral hepatitis in HIV infection. N Engl J Med 2007; 356:1445-1454. (Pubitemid 46556329)
30. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089. (Pubitemid 46763278)
31. Vispo E, Maida I, Barreiro P, Moreno V, Soriano V. Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV co-infected patients. HIV Clin Trials 2008; 9:440-444.